New England Legacy Gala Honors Leaders in Biotechnology, Innovation and Philanthropy

Recognizing Contributions to the Liver Community

The American Liver Foundation (ALF) recognizes individuals who have made an outstanding contribution to the liver community, fields of biotechnology, medical innovation, and philanthropy at the ALF New England Legacy Gala to be held at the Exchange Conference Center, May 5, 2022. The celebration will include a cocktail reception starting at 5:30 PM ET followed by desserts and a program.

“We are thrilled to have the opportunity to honor those making significant contributions to the liver community”, said Lorraine Stiehl, Chief Executive Officer of American Liver Foundation (ALF). “With nearly 100 million Americans affected by liver disease their collective work is more important now than ever.”

ALF will be honoring Jay Luly, Ph.D., and Thomas Sepe, MD. Dr. Luly is President, Chief Executive Officer and President at Enanta Pharmaceuticals, a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases. Dr. Sepe is a partner at University Gastroenterology in Providence and a Clinical Professor of Medicine at Brown University where he teaches medical students, medical residents, and gastroenterology fellows.  Dr. Sepe is a long-serving ALF New England Medical Advisor. Josh Korzenik, MD, will also present on the Brigham & Women’s Resnek Family Center for PSC Research, where he is the Lead Investigator.

For more information about the ALF New England Legacy Gala visit New England Gala (alfgala.org).

COVID-19 Alert

Your health and safety continue to be our number one priority. American Liver Foundation (ALF) staff, board of directors and healthcare advisors are closely monitoring the on-going COVID-19 pandemic. ALF will follow all local, state and federal guidelines. Absent any guidelines to the contrary, for ALF events held indoors or outdoors we recommend, but do not require, participants to wear masks and be appropriately vaccinated and boosted to best protect our patient population. If a change to the current event or program needs to be made, we will provide participants with detailed information on those changes regarding our COVID-19 safety policies.

Please Note: An inherent risk of exposure to COVID-19 exists in any public place where people are present. COVID-19 is an extremely contagious disease that can lead to severe illness and death. According to the Centers for Disease Control and Prevention, people with underlying medical conditions and older adults are especially vulnerable and need to take the appropriate recommended steps and precautions to prevent infection.

By attending an ALF in-person event, you acknowledge and voluntarily assume all risks related to exposure to COVID-19.

Last updated on August 9th, 2022 at 04:27 pm